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Circulating concentrations of tumor necrosis factor-a (TNF), interleukin (IL)-lP, IL-6, IL-l
receptor antagonist (lL-lra), and soluble TNF receptors p55 (sTNFr-55) and p75 (sTNFr-75)
and ex vivo production ofTNF, IL-l, IL-6, and IL-lra using a whole blood culture system were
measured during the acute and convalescent stages of meningococcal infection. Circulating TNF
and IL-l were below detection level, whereas IL-6 and IL-lra, sTNFr-55, and sTNFr-75 were
increased at admission. The ex vivo production of proinflammatory cytokines TNF, IL-l, and
IL-6 was suppressed at admission and restored gradually during recovery. On the contrary, the
production of the antiinflammatory IL-lra was increased at admission. The elevated concentra-
tions of both IL-lra and sTNFr early in the course of infection suggest a regulatory role for these
antiinflammatory compounds. The observed down-regulation of the ex vivo production ofTNF,
IL-l, and IL-6 and up-regulation of the production of IL-l ra in the acute stage may indicate a
protective regulation mechanism.
On contact with gram-negative bacteria or endotoxin (lipo-
polysaccharide, LPS), the immune-apparatus responds with
the production ofa broad spectrum ofcytokines. After injec-
tion ofLPS in human volunteers, the plasma concentrations
of the proinflammatory cytokines tumor necrosis factor-a
(TNF), interleukin (IL)-l {J, and IL-6 and the antiinflamma-
tory IL-I receptor antagonist (IL-I ra) rapidly increase [1-3].
Furthermore, the plasma concentrations of soluble TNF re-
ceptors p55 (sTNFr-55) and p75 (sTNFr-75) also rise [4,5].
Proinflammatory cytokines are thought to be essential for
an adequate host defense. However, excessive production of
TNF and IL-I causes shock, and high plasma concentrations
of TNF, IL-I, and IL-6 are associated with high mortality
rates [6-10]. This deleterious action of the proinflammatory
cytokines is balanced by sTNFr and lL-1 ra. Soluble TNF
receptors prevent the inflammatory effects of TNF by bind-
ing to TNF. High sTNFr/TNF plasma ratios were found to
be associated with a better prognosis [5, II]. IL-I ra blocks
the proinflammatory action of IL-I by competitive binding
to the IL-I receptor [12]; infusion of IL-I ra in experimental
shock prevents the shock and improves survival [13-15]. A
high production of IL-I ra during the acute stage of an infec-
tion may therefore be beneficial.
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The principle sources of these cytokines are blood mono-
cytes and tissue macrophages. On incubation with LPS, iso-
lated monocytes or whole blood taken from healthy donors
produce ex vivo cytokines in a spectrum similar to that ob-
served after LPS injection in volunteers. Without LPS stimu-
lation, there is no or minimal ex vivo cytokine production
[16, 17]. Several investigators have reported that during the
acute stage of serious infections, the ex vivo production of
TNF and IL-l is depressed [18-21]. The cause of this im-
paired production is unknown, but it has been considered as
a down-regulated state of the cytokine-producing cells, possi-
bly reflecting a protective mechanism by averting high con-
centrations of these cytokines [19, 21]. This hypothesis
would be supported if the production of the antiinflamma-
tory cytokine IL-l ra were inversely regulated and increased
during the acute stage.
We describe the pattern of circulating TNF, IL-I, IL-6,
IL-I ra, sTNFr-55, and sTNFr-75 and the ex vivo production
ofTNF, IL-l, IL-6, and IL-I ra during meningococcal infec-
tion.
Patients and Methods
Five patients with bacteriologically proven acute meningococ-
cal infections, admitted to our intensive care unit, were studied.
Four patients had meningitis without severe hemodynamic
complications, and I (patient 2) had mild sepsis without menin-
gitis. Some clinical parameters indicating the severity of disease
and prognosis are summarized in table 1. All patients received
antibiotics. Dexamethasone was given in different doses over
1-7 days (table I). Patient 2 was also treated with two exchange
transfusions [22]. All patients recovered completely, except pa-
tient 3 who developed sensorineural deafness.
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Table 1. Characteristics of the patients with meningococcal infections at admission and their dexamethasone therapy.
Disease period Plasma Dexamethasone therapy
before Blood Arterial HeO;- Leukocytes in Leukocytes in endotoxin
Patient no., hospitalization pressure concentration cerebrospinal peripheral blood concentration Duration Dose
sex/age (years) (h) (mm Hg) (rnrnol/L) fluid (X 106/L) (XI09/L) (pg/ml.) (days) (rug/kg/day)
L F/3 18 100/55 20.0 24,320 30.9 <12.5 3.5 1.000
2. F/5 16 80/50 16.9 II 7.3 162 4 0.600
3. M/6 36 110/85 17.0 13,800 19.2 <12.5 7 0.800
4. M/15 18 110/80 16.0 10.000 20.0 21 1.5 0.400
5. F/20 24 120/78 15.3 13,500 29.8 283 I 0.130
Serial plasma and serum samples were collected shortly after
admission and daily for 6 days. For endotoxin measurements, 2
mL of blood was drawn into 5-mL pyrogen-free plastic vials
(Falcon; Becton Dickinson Labware, Lincoln Park, NJ) contain-
ing 50 IV of pyrogen-free heparin and centrifuged at 200 g for
10 min. Plasma for cytokine assays was drawn into 4-mL tubes
(Vacutainer System; Becton Dickinson, Rutherford, NJ) con-
taining 48 JLL of 15% EDTA(K 3 ) and 250 JLL of aprotinin
(10,000 kallikrein-inactivating units/rnl.; Bayer, Leverkusen,
Germany). The tubes were centrifuged immediately at 2250 g
for 10 min and then at 15,000 g for 5 min to remove the plate-
lets. For IL-6 measurements serum was used. Aliquots were
stored at - 20 0 e until assay.
The ex vivo production of cytokines was measured in whole
blood using similar 4-mL tubes [23]. One tube was incubated
without LPS; in the other, 50 JLL ofLPS (final concentration, 10
JLg/mL; Escherichia coli 055:B5; Sigma, St Louis) was added
under sterile conditions. After 24 h of incubation at 37°C, both
tubes were centrifuged and handled as described above.
Endotoxin was measured in platelet-rich plasma by a chromo-
genic limulus amoebocyte lysate assay (KabiVitrum, Stock-
holm). TNF was determined by RIA as described by Van der
Meer et al. [24] (detection level, 100 pg/rnl.). IL-I was mea-
sured by RIA according to Lisi et al. [25] without chloroform
extraction (detection level, 80 pg/mL). IL-6 was measured by
ELISA as delineated by Barrera et al. [26] (detection level, 20
pg/rnl.). IL-I ra was determined by RIA according to Poutsiaka
et al. [17] (detection level, 300 pg/mL). sTNFr were measured
by an enzyme-linked immunobinding assay (Hoffmann-La
Roche; detection level, 80 pg/ml, for sTNFr-55 and 300 pg/mL
for sTNFr-75); normal values measured in 19 healthy volun-
teers were 1470 ± 190 pg/mL (median ± SD) for sTNFr-55 and
2520 ± 660 pg/mL for sTNFr-75. To minimize analytical
errors, all samples from the same patient were analyzed in the
same run in duplicate.
Results
Circulating cytokines and sTNFr. The plasma concentra-
tions ofTNF and IL-I were below detection level in all sam-
ples. At admission, IL-6 (range, 365-2550 pg/rnl.; median,
860), IL-I ra (range, 2840-4680 pg/rnl.; median, 3740),
sTNFr-55 (range, 2782-5215 pg/rnl.; median, 3873), and
sTNFr-75 (range, 5700-17282 pg/ml.; median, 12910)
were increased (figure I). Within 2 days, these concentra-
tions fell to normal levels.
Ex vivo cytokine production. The ex vivo production of
TNF without LPS stimulation was below detection level in
all samples. With LPS stimulation, TNF production was be-
low detection level during the acute stage of the disease.
After 3 days, during convalescence, this production gradu-
ally recovered to 8 10-3430 pg/mL (median, 2260) at day 6
(figure 2).
The course of IL-I production showed a similar pattern:
no measurable production at admission and restored LPS-
stimulated production during recovery at day 6 (range, 945-
4300 pg/ml.; median, 2325).
IL-6 was detectable at admission in unstimulated and in
LPS-stimulated tubes. However, after correction for the cir-
culating serum concentrations, the ex vivo production ofIL-
6 at admission was negligible. Similar to the pattern of ex
vivo production of TNF and IL-l, the LPS-stimulated pro-
duction ofIL-6 was restored during recovery, reaching 165-
9000 pg/mL (median, 2850) at day 6.
The ex vivo production of IL-I ra followed a different pat-
tern. At admission, the production ofIL-1 ra in both unstimu-
lated and LPS-stimulated cultures appeared to be increased.
The concentration at day 0 in the unstimulated tubes ranged
from 4450 to 6510 pg/rnl, (median, 5570); in the LPS-stimu-
lated tubes, this was 7080-12,990 pg/rnl, (median, 11,140).
The LPS-stimulated production decreased during the next 2
days toward a stable median of 6710 pg/rnl. from day 2 to
day 6. The unstimulated production declined gradually to-
ward a median of 1140 pg/ml, at days 4-6.
The ex vivo production of sTNFr was not measured be-
cause previous studies demonstrated that TNF receptors
were only minimally released in the whole blood culture sys-
tem on LPS stimulation (data not shown).
A similar pattern ofex vivo production was observed in all
patients, regardless of their leukocyte number or corticoste-
roid dose. Thus, the observed pattern in ex vivo cytokine
production was not influenced by these parameters.
Discussion
We followed the concentrations of circulating cytokines
and their ex vivo production during the course of meningo-
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5000 ..----------------,Figure 1. Circulating cytokine
concentrations and their inhibitors
during course of disease. Tumor
necrosis factor-a (TNF) and inter-
leukin (IL)-1{j were below detec-
tion levels (respectively, 100 and
80 pg/mL) in all samples and there-
fore are not shown. Left: patterns
oflL-6 (e) and IL-I receptor antag-
onist (0). Right: courses of soluble
TNF receptors p55 (e) and p75
(0). Median values have been in-
terpolated.
coccal infections. The onset of acute meningococcal infec-
tions is abrupt, with a rather short disease period before hospi-
talization. As such, meningococcal infections resemble
experimental models using endotoxin challenge.
In our patients, circulating TNF and IL-I concentrations
were all below detection level. Several factors may be respon-
sible for this negative finding. It may be possible that we
missed the initial cytokinemia. The disease period before ad-
mission ranged from 16 to 36 h, and it is known that after
LPS injection in human volunteers, TNF and IL-l levels
peak within 90-180 min [I, 2]. From clinical studies, we
know that high TNF concentrations occur early during se-
vere meningococcal infections [8-10]. The relatively low en-
dotoxin concentrations at admission, the good prognostic
score, and the absence of shock in 4 of the 5 patients may
also explain the low TNF and IL-l concentrations [8-10, 27,
28]. Finally, a slight increase in TNF and IL-I could have
been missed because of the relatively high detection level of
our assays. Recently, we have been able to detect rapidly
declining TNF and IL-l concentrations early in the course of
very severe and lethal meningococcal disease (unpublished
data). In the presen t series, actual activation of the cytokine
network was documented by elevated concentrations of IL-
6. Furthermore, the increased sTNFr-55 and sTNFr-75 lev-
els are compatible with TNF activity on target cells in tissues,
because binding of TNF to its receptors on these cells leads
to shedding of the extramembranous part of the receptor [5,
29]. IL-I ra concentrations were also elevated during the
acute stage. The high concentrations of both sTNFr and IL-
l ra early in the course of the infection suggest a regulating
role for these antiinflammatory compounds.
The LPS-stimulated ex vivo production of the proinflam-
matory cytokines TNF, IL-I, and IL-6 was suppressed during
the acute stage. Gradually the production capacity was re-
stored during reconvalescence. In contrast, the capacity to
produce ex vivo IL-I ra was regulated inversely (figure 2).
The LPS-stimulated IL-I ra production was maximal during
the acute stage and reached stability after 2 days. Moreover,
in the unstimulated cultures at admission, a spontaneous pro-
duction of IL-I ra was observed, which gradually decreased
during convalescence.
We used a whole blood culture system to measure the ex
vivo cytokine production. In vitro studies with isolated pe-
ripheral blood mononuclear cells (PBMC) or monocytes
Figure 2. Ex vivo cytokine pro-
duction of tumor necrosis factor-a
(TNF). interleukin (IL)-I{j, IL-6
and IL-I receptor antagonist (IL-
Ira) during course of disease. Left:
median concentrations (n = 5) in
whole blood cultures after 24 h
ex vivo incubation without lipo-
polysaccharide (LPS) stimulation.
Right: median concentrations after
incubation with 10 p,g/mL LPS.
pg/mL
15000
10000
5000
o 2 3 4 5 6
days after admission
pg/mL
15000
10000
5000
o 3 4 5 6
days after adm Isslon
160 van Deuren et at. JID 1994; 169 (January)
have yielded a substantial part ofour knowledge of the cyto-
kine response to infectious stimuli. However, isolation of
PBMC requires large blood volumes and is laborious and
difficult to organize. Whole blood culture systems are a suit-
able alternative in these circumstances [23, 30-32]. In addi-
tion, the whole blood system represents the cytokine re-
sponse of all types of cells present in blood at a certain time
point and may therefore be a more realistic assessment than
measurements using a fixed number of isolated and cultured
cells.
Impaired ex vivo production of the proinflammatory cyto-
kines TNF and IL-l during acute infection has been reported
by others [18-21]. Our study confirms these observations
but also shows that the impaired capacity to produce proin-
flammatory cytokines does not indicate that the cells present
in blood are completely refractory in terms of cytokine pro-
duction. Rather, they seem to have switched from a mainly
proinflammatory action (as in healthy individuals) to an an-
tiinflammatory action. During recovery, the cells gradually
switch again to the balanced proinflammatory status.
Further research should be done on the mechanism be-
hind this programmed switch. Our findings in meningococ-
cal infection may represent a process similar to endotoxin
tolerance, the phenomenon that survival in experimental an-
imals is markedly increased if a lethal dose of endotoxin is
preceded by a smaller dose. Inhibition of the production of
TNF, IL-l, and IL-6 is regarded as crucial [33]. Similarly, in
human volunteers receiving endotoxin intravenously, the ex
vivo production by CD 14+ cells of TNF, IL-l, and IL-6 is
significantly decreased [34]. IL-4 and IL-l 0 may playa role
in this process. IL-l 0 and IL-4 both down-regulate the LPS-
stimulated production by human PBMC and monocytes of
TNF, IL-l, and IL-6, whereas preincubation with IL-4 in-
creases the synthesis of IL-l ra [35-37]. Better insight into
these regulatory mechanisms may enable us to understand
why in some patients the invasion in the bloodstream of
Neisseria meningitidis induces high plasma concentrations of
TNF, IL-l, and IL-6 with severe shock, whereas in others a
localized meningitis develops with low systemic concentra-
tions ofthese cytokines [8-10]. Further study on these regula-
tory mechanisms may provide new therapeutic interven-
tions.
In conclusion, antiinflammatory compounds such as
sTNFr and IL-l ra are present in the circulation during early
meningococcal infection. The down-regulation of the pro-
duction of TNF, IL-l, and IL-6 and up-regulation of the
production of IL-l ra during acute infection could serve as a
mechanism of protection.
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